MA43876A - Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale - Google Patents

Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale

Info

Publication number
MA43876A
MA43876A MA043876A MA43876A MA43876A MA 43876 A MA43876 A MA 43876A MA 043876 A MA043876 A MA 043876A MA 43876 A MA43876 A MA 43876A MA 43876 A MA43876 A MA 43876A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
overload diseases
uses against
against lysosomal
lysosomal overload
Prior art date
Application number
MA043876A
Other languages
English (en)
Other versions
MA43876B1 (fr
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43876(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA43876A publication Critical patent/MA43876A/fr
Publication of MA43876B1 publication Critical patent/MA43876B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<!--startfragment-->la présente invention concerne le traitement de maladies de surcharge lysosomale (msl) comprenant l'administration d'acétyl-leucine ou d'un sel pharmaceutiquement acceptable de celle-ci.<!--endfragment-->
MA43876A 2016-08-11 2017-08-11 Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale MA43876B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale

Publications (2)

Publication Number Publication Date
MA43876A true MA43876A (fr) 2018-08-15
MA43876B1 MA43876B1 (fr) 2019-04-30

Family

ID=59859423

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43876A MA43876B1 (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA055947A MA55947A (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA055947A MA55947A (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial

Country Status (29)

Country Link
US (4) US11400067B2 (fr)
EP (4) EP4342461A3 (fr)
JP (4) JP7393943B2 (fr)
KR (4) KR102467953B1 (fr)
CN (3) CN109843275B (fr)
AU (3) AU2017308864B2 (fr)
CA (1) CA3033557A1 (fr)
CY (2) CY1121345T1 (fr)
DK (2) DK3482754T3 (fr)
ES (2) ES2849566T3 (fr)
HK (1) HK1253282B (fr)
HR (2) HRP20190344T1 (fr)
HU (2) HUE041914T2 (fr)
IL (2) IL264610B2 (fr)
LT (2) LT3482754T (fr)
MA (2) MA43876B1 (fr)
MD (2) MD3482754T2 (fr)
ME (1) ME03340B (fr)
MX (2) MX384447B (fr)
NZ (3) NZ750391A (fr)
PL (2) PL3482754T3 (fr)
PT (2) PT3359146T (fr)
RS (2) RS61442B1 (fr)
RU (1) RU2749515C2 (fr)
SG (1) SG11201901048VA (fr)
SI (2) SI3359146T1 (fr)
SM (2) SMT201900154T1 (fr)
TN (1) TN2019000032A1 (fr)
WO (1) WO2018029657A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
WO2020178721A1 (fr) 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie
SI3989962T1 (sl) 2019-06-28 2025-11-28 Intrabio Ltd Kombinirano zdravljenje z acetil-levcinom in miglustatom za zdravljenje lizosomske bolezni kopičenja
WO2022264037A1 (fr) * 2021-06-14 2022-12-22 Intrabio Ltd. Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
WO2001097829A2 (fr) * 2000-06-19 2001-12-27 Genzyme Corporation Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (fr) * 2008-03-14 2009-09-17 Irm Llc Composés, compositions et procédés de traitement des maladies et des troubles liés au stockage lysosomal
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) * 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
WO2013182652A1 (fr) * 2012-06-06 2013-12-12 Fondazione Telethon Chaperonnes allostériques et leurs utilisations
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
WO2018029658A1 (fr) 2016-08-11 2018-02-15 Intrabio Limited Agents thérapeutiques pour maladies neurodégénératives
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders

Also Published As

Publication number Publication date
AU2023202903A1 (en) 2023-05-25
EP3482754B1 (fr) 2020-12-23
MX384447B (es) 2025-03-14
US12433862B2 (en) 2025-10-07
RU2019106493A3 (fr) 2020-10-26
JP2025188157A (ja) 2025-12-25
ME03340B (fr) 2019-10-20
LT3359146T (lt) 2019-04-25
SG11201901048VA (en) 2019-03-28
RU2749515C2 (ru) 2021-06-11
SMT201900154T1 (it) 2019-05-10
US20220331278A1 (en) 2022-10-20
MX2021008432A (es) 2021-08-19
CN109843275A (zh) 2019-06-04
DK3482754T3 (da) 2021-02-01
KR102412724B1 (ko) 2022-06-23
JP7393943B2 (ja) 2023-12-07
ES2716133T3 (es) 2019-06-10
CN109843275B (zh) 2026-04-24
JP2024059863A (ja) 2024-05-01
KR20220044372A (ko) 2022-04-07
NZ790894A (en) 2026-03-27
US20260027077A1 (en) 2026-01-29
CA3033557A1 (fr) 2018-02-15
RS58478B1 (sr) 2019-04-30
WO2018029657A1 (fr) 2018-02-15
US20190201359A1 (en) 2019-07-04
IL314107A (en) 2024-09-01
PL3359146T3 (pl) 2019-07-31
EP3359146A1 (fr) 2018-08-15
US12433863B2 (en) 2025-10-07
AU2023202903B2 (en) 2025-03-06
IL264610B1 (en) 2024-08-01
KR20240110078A (ko) 2024-07-12
RU2021115932A (ru) 2021-06-08
HUE052837T2 (hu) 2021-05-28
PT3359146T (pt) 2019-03-27
KR20190039226A (ko) 2019-04-10
SI3482754T1 (sl) 2021-04-30
LT3482754T (lt) 2021-05-10
ES2849566T3 (es) 2021-08-19
IL264610B2 (en) 2024-12-01
NZ750391A (en) 2026-03-27
HRP20210153T1 (hr) 2021-05-28
MA55947A (fr) 2022-03-23
JP7757446B2 (ja) 2025-10-21
US11400067B2 (en) 2022-08-02
RS61442B1 (sr) 2021-03-31
IL264610A (en) 2019-02-28
HRP20190344T1 (hr) 2019-04-19
AU2017308864A1 (en) 2019-02-21
DK3359146T3 (en) 2019-04-08
SI3359146T1 (sl) 2019-05-31
KR20220154849A (ko) 2022-11-22
CN121360108A (zh) 2026-01-20
EP4342461A3 (fr) 2024-05-29
PT3482754T (pt) 2021-02-03
MX2019001577A (es) 2019-08-29
MD3482754T2 (ro) 2021-05-31
HK1253282A1 (en) 2019-06-14
EP3359146B1 (fr) 2019-01-23
MD3359146T2 (ro) 2019-04-30
JP2022050564A (ja) 2022-03-30
MA43876B1 (fr) 2019-04-30
AU2017308864B2 (en) 2023-06-01
TN2019000032A1 (en) 2020-07-15
RU2019106493A (ru) 2020-09-11
HUE041914T2 (hu) 2019-06-28
EP3482754A1 (fr) 2019-05-15
PL3482754T3 (pl) 2021-07-05
EP3865126A1 (fr) 2021-08-18
KR102467953B1 (ko) 2022-11-16
BR112019002719A2 (pt) 2019-05-14
SMT202100050T1 (it) 2021-03-15
CY1123844T1 (el) 2022-05-27
AU2025203479A1 (en) 2025-05-29
JP2019524821A (ja) 2019-09-05
HK1253282B (en) 2020-02-07
CN121360107A (zh) 2026-01-20
NZ790895A (en) 2026-03-27
US20240197663A1 (en) 2024-06-20
EP4342461A2 (fr) 2024-03-27
CY1121345T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
EP4374851A3 (fr) Composition ophtalmique pour le traitement d&#39;une maladie de l&#39; il sec
MA44674B1 (fr) Inhibiteurs de bromodomaine
EP4302834A3 (fr) 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu&#39;inhibiteurs allostériques de shp2
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
MX388457B (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n&#39;-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA40875B1 (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
PH12019502676A1 (en) Moisturizing topical preparation
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
WO2018033941A3 (fr) Compositions pharmaceutiques à base d&#39;ibrutinib
WO2018234871A3 (fr) Compositions pour administration de médicaments et leurs procédés d&#39;utilisation
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3404020A4 (fr) Dérivé de pyridinol ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique contenant celui-ci utilisé comme principe actif
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MA45639B1 (fr) Combinaison d&#39;antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d&#39;acétylcholinestérase
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
WO2019151964A3 (fr) Formulations de saxagliptine à délitement buccal
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
WO2018094035A3 (fr) Conjugués ligand-ionophore
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives